Background: Coagulation and fibrinolysis biomarkers can effectively reflect the dysfunction of coagulation and anticoagulation system, and the changes of their levels were closely related to the hypercoagulable status. The aim of this study is to study the variation tendency of these coagulation and fibrinolysis markers and explore the diagnosis power and clinical value of these biomarker for thrombosis in postoperative lung cancer patients with deep vein catheterization.
Methods: We selected 118 postoperative lung cancer patients with deep vein catheterization including 29 patients with thromboembolism and 89 patients in control group. Coagulation and fibrinolysis parameters [thrombomodulin (TM)/thrombin-antithrombin complex (TAT)/α2-plasmin inhibitor-plasmin complexes (PIC)/tissue plasminogen activator-inhibitor complexes (t-PAIC)] and traditional coagulation time[prothrombintime (PT)/activated partial thrombo plastin time(APTT)/thrombintime (TT)/fibrinogen (FIB)/antithrombin III (ATIII)/fibrinogen degradation products (FDP)/D-Dimer (D-D)] were detected in both groups. We analyzed the variation tendency of these biomarkers and figured out the diagnosis powerfor thrombosis.
Results: A statistically significant difference was available on the value of TM, TAT, PIC, t-PAIC, D-D, FDP between thrombosis group and non-thrombosis group (P<0.05). TM, TAT, PIC, t-PAIC, D-D, FDP performed with an AUC of 0.770, 0.771, 0.669, 0.671, 0.819, 0.816, respectively (P<0.05).
Conclusions: An enhanced coagulation and fibrinolysis activity existed in lung cancer patients with deep vein catheterization after surgery, and early detection of coagulation and fibrinolytic biomarkers could prevent thrombosis and reduce postoperative thrombosis complications in patients with lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105356 | PMC |
| http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.03 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in the detection of biomarkers for ischemic stroke.
Front Neurol
February 2025
Center for Clinical Laboratory, General Hospital of the Yangtze River Shipping, Wuhan Brain Hospital, Wuhan, Hubei, China.
Ischemic stroke is a leading cause of mortality and morbidity globally. Prompt intervention is essential for arresting disease progression and minimizing central nervous system damage. Although imaging studies play a significant role in diagnosing ischemic stroke, their high costs and limited sensitivity often result in diagnostic and treatment delays.
View Article and Find Full Text PDFThe Role of Coagulation/Fibrinolysis Biomarkers in Pathophysiology, Disease Severity, and Treatment Response in Patients with Urticaria: A Scoping Review.
Clin Rev Allergy Immunol
March 2025
Department of Acupuncture and Massage, Shenzhen Second People's Hospital, Futian District, Sungang West Road, Shenzhen, Guangdong Province, 3002, China.
The pathology of urticaria is complex. Recently, researchers have widely focused on the role that the coagulation/fibrinolysis system plays in the pathology of urticaria. The potential of coagulation/fibrinolysis biomarkers as disease severity or treatment response biomarkers remains uncertain, lacking comprehensive analysis in previous studies.
View Article and Find Full Text PDFPatients with cirrhosis have a disbalance between coagulation and fibrinolysis resulting in a prothrombotic phenotype.
J Thromb Haemost
March 2025
Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands; Department of Platelet Pathophysiology, Synapse Research Institute, Maastricht, the Netherlands.
Background: Patients with cirrhosis develop multiple hemostatic alterations. Although fibrinolysis is also affected by liver disease, studies have produced conflicting results, highlighting the need for a reliable fibrinolysis assay. Assessing the kinetics of plasmin generation (PG) is a new method to study the fibrinolytic state of cirrhosis patients.
View Article and Find Full Text PDFBleeding symptoms in persons with rare bleeding disorders and a heterozygous genotype: data from the RBiN study.
J Thromb Haemost
March 2025
Department of Hematology, Radboud university medical center, Nijmegen, The Netherlands; Hemophilia Treatment Center, Nijmegen - Eindhoven - Maastricht, The Netherlands. Electronic address:
Background: Limited data exists on persons with rare bleeding disorders (RBDs) possessing a heterozygous genotype, as most studies focus on bi-allelic genotypes and more severe coagulation factor deficiencies. A growing body of evidence suggests that persons with a heterozygous genotype experience clinically relevant bleeding symptoms.
Objectives: Explore the incidence of bleeding symptoms and postoperative bleeding in persons with a heterozygous genotype.
Characterization of Fibrinolytic Enzyme from Bacillus altitudinis S-CSR 0020 and Its Clot-Degrading Capacity.
Curr Microbiol
March 2025
Department of Microbiology, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, 641021, India.
Thrombosis, the major cause of heart disease, is on the rise owing to the current lifestyle habits of the population. Current treatments using thrombolytics, although successful, are plagued by side effects and costs. Fibrinolytic enzymes derived from microbial sources are ideal substitutes for chemical thrombolytics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!